{
    "hands_on_practices": [
        {
            "introduction": "Before administering intravenous thrombolysis, a rapid and rigorous assessment for contraindications is paramount to ensure patient safety. This process requires balancing the potential benefit of arterial recanalization against the significant risk of iatrogenic hemorrhage, which is amplified by underlying coagulopathies. This exercise  challenges you to apply foundational knowledge of hemostasis and formalize the clinical decision-making process by integrating key laboratory values, such as the $\\text{INR}$ and platelet count, into a logical eligibility framework.",
            "id": "4487496",
            "problem": "A patient with acute ischemic stroke presents within the therapeutic time window for Recombinant Tissue Plasminogen Activator (rt-PA, alteplase). The patient is chronically anticoagulated with warfarin for atrial fibrillation. The following foundational facts and definitions are available for decision-making about intravenous thrombolysis: (i) International Normalized Ratio (INR) is defined by $$\\text{INR} = \\left(\\frac{\\text{PT}_{\\text{patient}}}{\\text{PT}_{\\text{normal}}}\\right)^{\\text{ISI}}$$ and reflects the intensity of anticoagulation via suppression of vitamin K-dependent clotting factors in the extrinsic and common coagulation pathways; (ii) alteplase catalyzes conversion of plasminogen to plasmin, accelerating fibrinolysis and degrading fibrin; (iii) excessively impaired coagulation increases the probability of symptomatic intracerebral hemorrhage when coupled with fibrinolysis; and (iv) widely used, evidence-based exclusion criteria for intravenous alteplase consider warfarin-treated patients ineligible when $\\text{INR} > 1.7$ and patients with thrombocytopenia ineligible when platelet count is below $100,000/\\mu\\text{L}$. The patient’s laboratory values just prior to consideration of thrombolysis are $\\text{INR}=1.6$ and platelet count $P=220 \\times 10^3/\\mu\\text{L}$. The neurological examination reveals a disabling deficit (for concreteness, assume National Institutes of Health Stroke Scale (NIHSS) $=8$ with aphasia), and all other standard contraindications are absent.\n\nStarting from the interaction between warfarin-induced hypocoagulability quantified by $\\text{INR}$ and alteplase-induced fibrinolysis, explain why $\\text{INR}>1.7$ in the setting of warfarin therapy constitutes a contraindication to intravenous alteplase administration. Then, formalize a binary eligibility indicator $E$ for alteplase as a product of logically justified criteria reflecting hemostatic adequacy and disabling deficit, and compute $E$ for the given patient values of $\\text{INR}=1.6$, $P=220 \\times 10^3/\\mu\\text{L}$, and the presence of a disabling deficit.\n\nExpress the final eligibility indicator as a unitless number. No rounding is required.",
            "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. It is based on established principles of stroke neurology and coagulation physiology, provides all necessary data for a logical deduction, and is free of ambiguity or contradiction.\n\nThe problem asks for two parts: first, an explanation of the contraindication for intravenous alteplase when the International Normalized Ratio ($\\text{INR}$) exceeds $1.7$ in a patient on warfarin, and second, the formalization and calculation of a binary eligibility indicator for a specific patient.\n\nPart 1: Explanation of the $\\text{INR} > 1.7$ Contraindication\n\nHemostasis, the physiological process that stops bleeding, relies on a delicate equilibrium between pro-coagulant and anti-coagulant factors, as well as fibrinolytic and anti-fibrinolytic systems. A key component of a stable blood clot is a mesh of fibrin polymers.\n\nWarfarin is an anticoagulant that functions by inhibiting the synthesis of vitamin K-dependent clotting factors. As stated in the problem, this affects the extrinsic and common pathways of the coagulation cascade. The $\\text{INR}$, defined as $$\\text{INR} = \\left(\\frac{\\text{PT}_{\\text{patient}}}{\\text{PT}_{\\text{normal}}}\\right)^{\\text{ISI}}$$, quantifies the degree of this induced hypocoagulability. A higher $\\text{INR}$ signifies a greater impairment of the blood's ability to form clots.\n\nAlteplase (rt-PA) is a fibrinolytic agent. Its mechanism of action, as given, is to catalyze the conversion of plasminogen to plasmin. Plasmin is a potent enzyme that degrades fibrin, thereby dissolving existing blood clots. This action is the therapeutic basis for its use in acute ischemic stroke, where the goal is to dissolve the thrombus occluding a cerebral artery.\n\nThe administration of a powerful fibrinolytic agent like alteplase to a patient with a pre-existing coagulopathy presents a significant synergistic risk. The patient's ability to form new clots is already compromised by warfarin, as indicated by an elevated $\\text{INR}$. Simultaneously, alteplase is actively degrading fibrin, which is essential not only for the pathologic thrombus but also for maintaining vascular integrity throughout the body, particularly in the brain, which is susceptible to hemorrhagic transformation after an ischemic insult.\n\nIf the baseline coagulation system is too impaired (i.e., if the $\\text{INR}$ is too high), the systemic lytic state induced by alteplase can overwhelm the body's compromised hemostatic defenses. This leads to a substantially increased risk of bleeding complications. The most feared of these is symptomatic intracerebral hemorrhage (sICH), a catastrophic event with high morbidity and mortality. The statement \"excessively impaired coagulation increases the probability of symptomatic intracerebral hemorrhage when coupled with fibrinolysis\" directly summarizes this interaction.\n\nThe specific threshold of $\\text{INR} > 1.7$ is not a theoretical construct but an evidence-based cutoff derived from major clinical trials of thrombolysis. These studies demonstrated that for patients on warfarin with an $\\text{INR}$ above this level, the risk of sICH was unacceptably high and outweighed the potential benefits of reperfusion. Therefore, $\\text{INR} > 1.7$ serves as a critical safety exclusion criterion to mitigate the risk of life-threatening iatrogenic hemorrhage.\n\nPart 2: Formalization and Calculation of the Eligibility Indicator\n\nThe problem requires the formalization of a binary eligibility indicator, $E$, as a product of logically justified criteria. A binary indicator takes the value $1$ for \"true\" (eligible) and $0$ for \"false\" (ineligible). A product ensures that all criteria must be met for eligibility. If any single criterion evaluates to $0$, the overall eligibility $E$ becomes $0$.\n\nBased on the problem statement, we can identify three essential criteria for this patient:\n$1$. The presence of a disabling deficit, which is the primary indication for treatment. Let this be $C_{deficit}$.\n$2$. An acceptable level of anticoagulation from warfarin, defined by $\\text{INR} \\le 1.7$. Let this be $C_{INR}$.\n$3$. An adequate platelet count for primary hemostasis, defined by platelet count $P \\ge 100,000/\\mu\\text{L}$. Let this be $C_{platelet}$.\n\nWe can formalize these as binary functions:\n- $C_{deficit} = 1$ if a disabling deficit is present, and $0$ otherwise.\n- $C_{INR} = 1$ if $\\text{INR} \\le 1.7$, and $0$ if $\\text{INR} > 1.7$.\n- $C_{platelet} = 1$ if $P \\ge 100 \\times 10^3/\\mu\\text{L}$, and $0$ if $P  100 \\times 10^3/\\mu\\text{L}$.\n\nThe eligibility indicator $E$ is the product of these criteria:\n$$E = C_{deficit} \\cdot C_{INR} \\cdot C_{platelet}$$\n\nNow, we compute $E$ using the patient's specific data:\n- The patient has a \"disabling deficit (NIHSS $=8$ with aphasia)\". Thus, $C_{deficit} = 1$.\n- The patient's $\\text{INR}$ is $1.6$. The condition is $1.6 \\le 1.7$, which is true. Thus, $C_{INR} = 1$.\n- The patient's platelet count is $P = 220 \\times 10^3/\\mu\\text{L}$. The condition is $220 \\times 10^3/\\mu\\text{L} \\ge 100 \\times 10^3/\\mu\\text{L}$, which is true. Thus, $C_{platelet} = 1$.\n\nSubstituting these values into the expression for $E$:\n$$E = 1 \\cdot 1 \\cdot 1 = 1$$\n\nThe value of the eligibility indicator $E$ is $1$, indicating that the patient is eligible for intravenous alteplase based on the provided information and criteria.",
            "answer": "$$\\boxed{1}$$"
        },
        {
            "introduction": "Severe hypertension is a relative but critical contraindication for intravenous thrombolysis, as elevated blood pressure significantly increases the risk of hemorrhagic transformation in the setting of pharmacologic reperfusion. Safely and rapidly lowering blood pressure to meet eligibility criteria requires a quantitative understanding of antihypertensive drug pharmacodynamics. This practice  simulates the dynamic, real-time challenge of titrating an intravenous agent like nicardipine, using a first-order model to develop a precise, goal-directed treatment plan essential for pre-thrombolysis patient optimization.",
            "id": "4487626",
            "problem": "A patient with acute ischemic stroke is being prepared for Intravenous Thrombolysis (IVT). The patient’s Systolic Blood Pressure (SBP) is $205$ $\\mathrm{mmHg}$, and IVT cannot be initiated until SBP is reduced to at most $185$ $\\mathrm{mmHg}$. To minimize hemorrhagic risk and provide a safety margin, the treatment team selects a target SBP of $175$ $\\mathrm{mmHg}$ to be achieved within $10$ minutes using a continuous intravenous nicardipine infusion. In this institution, nicardipine is titrated in increments of $2.5$ $\\mathrm{mg/h}$, with a maximum infusion rate of $15$ $\\mathrm{mg/h}$.\n\nAssume a first-order effect-site pharmacodynamic model that starts from the following bases:\n- Drug delivery into the body obeys mass balance and constant-rate input: an infusion at rate $r(t)$ (in $\\mathrm{mg/h}$) produces a concentration-time profile that is approximately reflected in the effect-site with a characteristic time constant $\\tau$ (in minutes).\n- The nicardipine-induced reduction in SBP, denoted $E(t)$ (in $\\mathrm{mmHg}$), approaches its steady state proportionally to the infusion rate, with proportionality constant $\\beta$ (in $\\mathrm{mmHg}/(\\mathrm{mg/h})$), but exhibits a first-order lag governed by $\\tau$. Thus, $E(t)$ tends toward the steady-state value $E_{\\infty}=\\beta\\,r(t)$ with exponential approach.\n\nUse the following scientifically plausible parameters reflecting nicardipine’s rapid onset and potency in acute stroke blood pressure management:\n- Time constant $\\tau=5$ minutes.\n- Potency slope $\\beta=2.5$ $\\mathrm{mmHg}/(\\mathrm{mg/h})$.\n\nConstruct a titration plan that begins at $5$ $\\mathrm{mg/h}$ and increases by $2.5$ $\\mathrm{mg/h}$ at uniform monitoring intervals, without exceeding $15$ $\\mathrm{mg/h}$, to reach SBP $175$ $\\mathrm{mmHg}$ by $10$ minutes. Your plan must:\n- Specify the monitoring interval in minutes.\n- Specify the minute-by-minute infusion rates $r(t)$ over the $10$-minute window.\n- Be justified by deriving, from the first-order approach to steady state, how stepwise constant infusion segments cumulatively determine $E(10)$ and thus the predicted SBP $P(10)=205-E(10)$.\n\nFinally, compute the total nicardipine dose delivered over the $10$-minute period, expressed in $\\mathrm{mg}$. Round your final numerical answer to four significant figures and express it in $\\mathrm{mg}$.",
            "solution": "The problem is scientifically and mathematically well-posed, providing a consistent and complete set of data, constraints, and objectives. All parameters are physically and clinically realistic. Therefore, the problem is valid and a solution can be constructed.\n\nThe primary objective is to reduce the Systolic Blood Pressure (SBP) from an initial value of $P_0 = 205$ $\\mathrm{mmHg}$ to a target of $P_{target} = 175$ $\\mathrm{mmHg}$ within $T = 10$ minutes. This requires a total SBP reduction of $E_{target} = P_0 - P_{target} = 205 - 175 = 30$ $\\mathrm{mmHg}$.\n\nThe pharmacodynamic model for the SBP reduction $E(t)$ is given by a first-order process:\n$$ \\frac{dE}{dt} = \\frac{1}{\\tau} (E_{\\infty} - E(t)) $$\nwhere $E_{\\infty} = \\beta r(t)$ is the steady-state SBP reduction for a constant infusion rate $r(t)$, $\\tau=5$ minutes is the time constant, and $\\beta=2.5$ $\\mathrm{mmHg}/(\\mathrm{mg/h})$ is the potency slope. Substituting $E_{\\infty}$, we have the governing first-order linear ordinary differential equation:\n$$ \\frac{dE}{dt} + \\frac{1}{\\tau} E(t) = \\frac{\\beta}{\\tau} r(t) $$\nThe initial condition is $E(0)=0$, as there is no drug effect at time $t=0$.\n\nThe infusion rate $r(t)$ is a piecewise constant function. The rate starts at $r_0 = 5$ $\\mathrm{mg/h}$ and is increased by increments of $\\Delta r = 2.5$ $\\mathrm{mg/h}$ at uniform monitoring intervals of duration $\\Delta t$, up to a maximum rate of $r_{max} = 15$ $\\mathrm{mg/h}$.\n\nWe can solve the differential equation for a general piecewise constant input. For a time interval $[t_k, t_{k+1}]$ during which the rate $r(t) = r_k$ is constant, the solution is:\n$$ E(t) = E(t_k) \\exp\\left(-\\frac{t-t_k}{\\tau}\\right) + \\beta r_k \\left(1 - \\exp\\left(-\\frac{t-t_k}{\\tau}\\right)\\right) $$\nwhere $E(t_k)$ is the SBP reduction at the beginning of the interval.\n\nWe must determine the monitoring interval $\\Delta t$ such that the titration plan achieves $E(10) \\approx 30$ $\\mathrm{mmHg}$. Let's test a plausible interval, $\\Delta t = 1$ minute. The rate changes will occur at $t=1, 2, 3, \\ldots$ minutes.\nThe titration plan is as follows:\n- At $t=0$ min: Start infusion at $r_0 = 5$ $\\mathrm{mg/h}$.\n- At $t=1$ min: Increase rate to $r_1 = 5 + 2.5 = 7.5$ $\\mathrm{mg/h}$.\n- At $t=2$ min: Increase rate to $r_2 = 7.5 + 2.5 = 10$ $\\mathrm{mg/h}$.\n- At $t=3$ min: Increase rate to $r_3 = 10 + 2.5 = 12.5$ $\\mathrm{mg/h}$.\n- At $t=4$ min: Increase rate to $r_4 = 12.5 + 2.5 = 15$ $\\mathrm{mg/h}$.\nThe rate now reaches the maximum allowed value, $r_{max}=15$ $\\mathrm{mg/h}$, and will be maintained at this level for the remainder of the $10$-minute period.\n\nThe infusion rates $r(t)$ over the $10$-minute window are:\n- For $t \\in [0, 1)$ min, $r(t) = 5$ $\\mathrm{mg/h}$.\n- For $t \\in [1, 2)$ min, $r(t) = 7.5$ $\\mathrm{mg/h}$.\n- For $t \\in [2, 3)$ min, $r(t) = 10$ $\\mathrm{mg/h}$.\n- For $t \\in [3, 4)$ min, $r(t) = 12.5$ $\\mathrm{mg/h}$.\n- For $t \\in [4, 10]$ min, $r(t) = 15$ $\\mathrm{mg/h}$.\n\nNow, we justify this plan by calculating the SBP reduction $E(10)$ using the iterative solution. We have $\\tau=5$ min and $\\beta=2.5$ $\\mathrm{mmHg}/(\\mathrm{mg/h})$.\n\nFor $t \\in [0, 1)$:\n$E(1) = E(0)\\exp(-1/5) + \\beta r_0 (1-\\exp(-1/5)) = 0 + (2.5)(5)(1-\\exp(-0.2)) = 12.5(1-\\exp(-0.2))$.\n$E(1) \\approx 12.5(1-0.81873) = 2.26588$ $\\mathrm{mmHg}$.\n\nFor $t \\in [1, 2)$:\n$E(2) = E(1)\\exp(-1/5) + \\beta r_1 (1-\\exp(-1/5)) = 2.26588\\exp(-0.2) + (2.5)(7.5)(1-\\exp(-0.2))$.\n$E(2) \\approx 2.26588(0.81873) + 18.75(0.18127) \\approx 1.85511 + 3.39881 = 5.25392$ $\\mathrm{mmHg}$.\n\nFor $t \\in [2, 3)$:\n$E(3) = E(2)\\exp(-1/5) + \\beta r_2 (1-\\exp(-1/5)) = 5.25392\\exp(-0.2) + (2.5)(10)(1-\\exp(-0.2))$.\n$E(3) \\approx 5.25392(0.81873) + 25(0.18127) \\approx 4.30172 + 4.53175 = 8.83347$ $\\mathrm{mmHg}$.\n\nFor $t \\in [3, 4)$:\n$E(4) = E(3)\\exp(-1/5) + \\beta r_3 (1-\\exp(-1/5)) = 8.83347\\exp(-0.2) + (2.5)(12.5)(1-\\exp(-0.2))$.\n$E(4) \\approx 8.83347(0.81873) + 31.25(0.18127) \\approx 7.23250 + 5.66469 = 12.89719$ $\\mathrm{mmHg}$.\n\nFor the final interval, $t \\in [4, 10]$, the duration is $10-4=6$ minutes.\n$E(10) = E(4)\\exp(-6/5) + \\beta r_4 (1-\\exp(-6/5)) = 12.89719\\exp(-1.2) + (2.5)(15)(1-\\exp(-1.2))$.\n$E(10) \\approx 12.89719(0.30119) + 37.5(1-0.30119) \\approx 3.88452 + 37.5(0.69881) = 3.88452 + 26.20538 = 30.0899$ $\\mathrm{mmHg}$.\n\nThe predicted SBP at $t=10$ minutes is $P(10) = P_0 - E(10) = 205 - 30.0899 \\approx 174.91$ $\\mathrm{mmHg}$. This result is negligibly different from the target SBP of $175$ $\\mathrm{mmHg}$, validating the titration plan with a $1$-minute monitoring interval.\n\nFinally, we compute the total dose of nicardipine administered over the $10$-minute period. The total dose $D$ is the time integral of the infusion rate $r(t)$. Since the rates are in $\\mathrm{mg/h}$ and time intervals are in minutes, we must include a conversion factor of $1/60$ $\\mathrm{h/min}$.\n$$ D = \\frac{1}{60} \\sum_{k} r_k \\cdot \\Delta t_k $$\nwhere $r_k$ is the rate during the interval of duration $\\Delta t_k$ (in minutes).\n\n$D = \\frac{1}{60} [(5 \\, \\mathrm{mg/h} \\cdot 1 \\, \\mathrm{min}) + (7.5 \\, \\mathrm{mg/h} \\cdot 1 \\, \\mathrm{min}) + (10 \\, \\mathrm{mg/h} \\cdot 1 \\, \\mathrm{min}) + (12.5 \\, \\mathrm{mg/h} \\cdot 1 \\, \\mathrm{min}) + (15 \\, \\mathrm{mg/h} \\cdot 6 \\, \\mathrm{min})]$\n$D = \\frac{1}{60} [5 + 7.5 + 10 + 12.5 + 90]$\n$D = \\frac{1}{60} [125]$\n$D = \\frac{125}{60} = \\frac{25}{12} \\approx 2.08333...$ $\\mathrm{mg}$.\n\nRounding the final answer to four significant figures, we get $D = 2.083$ $\\mathrm{mg}$.\n\nThe constructed titration plan is as follows:\n1.  **Monitoring Interval**: $1$ minute.\n2.  **Infusion Plan**:\n    - Begin nicardipine infusion at $5$ $\\mathrm{mg/h}$.\n    - At $1$-minute intervals, increase the rate by $2.5$ $\\mathrm{mg/h}$ until the rate reaches $15$ $\\mathrm{mg/h}$ at $t=4$ minutes.\n    - Continue the infusion at $15$ $\\mathrm{mg/h}$ until $t=10$ minutes.\nThis plan is predicted to achieve the target SBP of $175$ $\\mathrm{mmHg}$ at $10$ minutes. The total dose administered is calculated as above.",
            "answer": "$$ \\boxed{2.083} $$"
        },
        {
            "introduction": "Once a patient is confirmed to be an eligible candidate and all prerequisites, such as blood pressure control, are met, the accurate calculation and administration of alteplase is the final, critical executive step. The dosing regimen follows a standardized, weight-based protocol that includes a maximum dose cap to mitigate toxicity and a specific bolus-infusion sequence to rapidly achieve and then maintain a therapeutic concentration. This fundamental calculation  reinforces the core skills required for safe drug delivery, ensuring that established pharmacological principles are correctly translated into action at the bedside.",
            "id": "4487600",
            "problem": "A patient with acute ischemic stroke is being treated with intravenous recombinant tissue plasminogen activator (alteplase). The patient’s body weight is $72$ kg. According to the approved dosing regimen for alteplase in acute ischemic stroke, dosing is weight-based at $0.9$ mg/kg with a maximum total dose cap of $90$ mg, administered as an intravenous bolus of ten percent of the total dose followed by an infusion of the remainder over $60$ minutes. Using only these foundational clinical rules and first principles of proportional dosing and capping, determine the following three quantities for this patient:\n- the total alteplase dose in mg,\n- the bolus dose in mg,\n- the infusion dose in mg to be delivered over $60$ minutes.\n\nExpress all three quantities in milligrams (mg). Round each quantity to three significant figures. Provide your final answer as a single row matrix containing, in order, the total dose, the bolus dose, and the infusion dose.",
            "solution": "The problem statement is validated as scientifically grounded, well-posed, and objective. It provides a complete and consistent set of clinical parameters for a standard pharmacological calculation. The principles described—weight-based dosing, a maximum dose cap, and a bolus-infusion split—are established and formalized in clinical guidelines for intravenous thrombolysis in acute ischemic stroke. No scientific flaws, ambiguities, or contradictions are present.\n\nThe solution proceeds by a direct application of the specified clinical algorithm. We will first determine the total dose by calculating the weight-based dose and comparing it against the maximum allowed dose. Subsequently, the bolus and infusion doses will be calculated based on the determined total dose.\n\nLet the patient's body weight be denoted by $W$. The given value is $W = 72~\\text{kg}$.\nThe weight-based dosing rate is $D_{\\text{rate}} = 0.9~\\text{mg/kg}$.\nThe maximum total dose cap is $D_{\\text{max}} = 90~\\text{mg}$.\n\nFirst, we calculate the theoretical total dose based on the patient's weight, which we shall call $D_{\\text{calc}}$:\n$$D_{\\text{calc}} = W \\times D_{\\text{rate}}$$\nSubstituting the given values:\n$$D_{\\text{calc}} = 72 \\text{ kg} \\times 0.9 \\frac{\\text{mg}}{\\text{kg}} = 64.8 \\text{ mg}$$\n\nNext, we must apply the maximum dose constraint. The actual total dose to be administered, denoted $D_{\\text{total}}$, is the lesser of the calculated dose and the maximum dose cap:\n$$D_{\\text{total}} = \\min(D_{\\text{calc}}, D_{\\text{max}})$$\n$$D_{\\text{total}} = \\min(64.8 \\text{ mg}, 90 \\text{ mg}) = 64.8 \\text{ mg}$$\nThe problem requires rounding to three significant figures. The value $64.8$ already has three significant figures. Thus, the total dose is $64.8~\\text{mg}$.\n\nThe intravenous bolus dose, denoted $D_{\\text{bolus}}$, is specified as ten percent ($10\\%$) of the total dose:\n$$D_{\\text{bolus}} = 0.10 \\times D_{\\text{total}}$$\n$$D_{\\text{bolus}} = 0.10 \\times 64.8 \\text{ mg} = 6.48 \\text{ mg}$$\nThis value, $6.48$, also has three significant figures. Thus, the bolus dose is $6.48~\\text{mg}$.\n\nFinally, the infusion dose, denoted $D_{\\text{infusion}}$, is the remainder of the total dose after the bolus is administered. It can be calculated as $90\\%$ of the total dose or by subtraction:\n$$D_{\\text{infusion}} = D_{\\text{total}} - D_{\\text{bolus}}$$\n$$D_{\\text{infusion}} = 64.8 \\text{ mg} - 6.48 \\text{ mg} = 58.32 \\text{ mg}$$\nWe must round this value to three significant figures. The first three significant figures are $5$, $8$, and $3$. The fourth digit is $2$, which is less than $5$, so we round down.\n$$D_{\\text{infusion}} \\approx 58.3 \\text{ mg}$$\n\nTherefore, the three required quantities, rounded to three significant figures, are:\n- Total alteplase dose: $64.8~\\text{mg}$.\n- Bolus dose: $6.48~\\text{mg}$.\n- Infusion dose: $58.3~\\text{mg}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n64.8  6.48  58.3\n\\end{pmatrix}\n}\n$$"
        }
    ]
}